{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:07:53Z","timestamp":1790262473469,"version":"4.1.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Gene therapy for sickle cell disease and transfusion-dependent thalassemia is now widely available, yet its broader application is constrained by the need for effective and tolerable conditioning. This review examines the central role of conditioning in enabling durable engraftment of gene-modified hematopoietic stem cells, emphasizing the narrow therapeutic window between insufficient niche clearance and excessive toxicity. Busulfan remains the standard conditioning agent, supported by consistent engraftment and clinical efficacy, but its use is limited by acute and long-term toxicities, including infertility and potential genotoxicity. Emerging strategies aim to mitigate these risks. Reduced-intensity melphalan shows early promise but raises concerns regarding the durability of engraftment, whereas treosulfan offers a potentially safer profile, although data in the autologous setting are lacking. Antibody-based, nongenotoxic approaches represent a transformative direction but remain investigational. Refining conditioning through comparative trials and long-term follow-up will be critical to fully realize the curative potential of gene therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019856","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:18:16Z","timestamp":1783531096000},"page":"6118-6123","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Alternative conditioning regimens for hemoglobinopathy gene therapy: balancing efficacy, toxicity, and the next frontier"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"first","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[{"name":"2Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"3","key":"2026092410311012600_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2022.08.003","article-title":"Editing human hematopoietic stem cells: advances and challenges","volume":"25","author":"Bhoopalan","year":"2023","journal-title":"Cytotherapy"},{"issue":"11","key":"2026092410311012600_bib2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jcyt.2024.06.002","article-title":"International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell\u2013based genomic therapies and the challenges faced","volume":"26","author":"Gupta","year":"2024","journal-title":"Cytotherapy"},{"issue":"26","key":"2026092410311012600_bib3","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood.2024024519","article-title":"How I treat sickle cell disease with gene therapy","volume":"144","author":"Sharma","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026092410311012600_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"2026092410311012600_bib5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"2026092410311012600_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026092410311012600_bib7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N Engl J Med"},{"issue":"10468","key":"2026092410311012600_bib8","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","article-title":"Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial","volume":"404","author":"Kwiatkowski","year":"2024","journal-title":"Lancet"},{"issue":"18","key":"2026092410311012600_bib9","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"2026092410311012600_bib10","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMoa2415550","article-title":"CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat sickle cell disease","volume":"394","author":"Hanna","year":"2026","journal-title":"N Engl J Med"},{"issue":"18","key":"2026092410311012600_bib11","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2504835","article-title":"Base editing of HBG1 and HBG2 promoters for sickle cell disease","volume":"394","author":"Gupta","year":"2026","journal-title":"N Engl J Med"},{"issue":"13","key":"2026092410311012600_bib12","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2501277","article-title":"CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat \u03b2-thalassemia","volume":"394","author":"Frangoul","year":"2026","journal-title":"N Engl J Med"},{"issue":"15","key":"2026092410311012600_bib13","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1182\/bloodadvances.2024015413","article-title":"To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients","volume":"9","author":"Sharma","year":"2025","journal-title":"Blood Adv"},{"issue":"21","key":"2026092410311012600_bib14","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1182\/bloodadvances.2024012963","article-title":"Listening to patients and parents with sickle cell disease: the totality of gene therapy risks may outweigh the perceived benefits","volume":"8","author":"Johnson","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2026092410311012600_bib15","doi-asserted-by":"crossref","first-page":"e30319","DOI":"10.1002\/pbc.30319","article-title":"Gene therapy in sickle cell disease: attitudes and informational needs of patients and caregivers","volume":"70","author":"Sharma","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2026092410311012600_bib16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2026092410311012600_bib17","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/s41591-025-03662-2","article-title":"Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1\/2 trial","volume":"31","author":"Grimley","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"2026092410311012600_bib18","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"issue":"10","key":"2026092410311012600_bib19","first-page":"1007.e1","article-title":"Busulfan exposure target attainment in adults undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiple day therapeutic drug monitoring regimen","volume":"30","author":"Bogn\u00e0r","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"2026092410311012600_bib20","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41409-024-02413-0","article-title":"A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"59","author":"Domingos","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2026092410311012600_bib21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026092410311012600_bib22","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2026092410311012600_bib23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat Genet"},{"issue":"1","key":"2026092410311012600_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41588-022-01257-y","article-title":"Human genetic diversity alters off-target outcomes of therapeutic gene editing","volume":"55","author":"Cancellieri","year":"2023","journal-title":"Nat Genet"},{"issue":"14","key":"2026092410311012600_bib25","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1056\/NEJMc2503294","article-title":"Specificity of CRISPR-Cas9 editing in exagamglogene autotemcel\u2014update","volume":"393","author":"Yen","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"2026092410311012600_bib26","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/bloodadvances.2024013275","article-title":"Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity","volume":"8","author":"Bogn\u00e0r","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2026092410311012600_bib27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/FTD.0000000000001107","article-title":"Busulfan interlaboratory proficiency testing program revealed worldwide errors in drug quantitation and dose recommendations","volume":"45","author":"Kweekel","year":"2023","journal-title":"Ther Drug Monit"},{"issue":"5","key":"2026092410311012600_bib28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/FTD.0000000000000862","article-title":"Quality control of busulfan plasma quantitation, modeling, and dosing: an interlaboratory proficiency testing program","volume":"43","author":"McCune","year":"2021","journal-title":"Ther Drug Monit"},{"issue":"7","key":"2026092410311012600_bib29","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jtct.2026.03.019","article-title":"Gene therapy for sickle cell disease: practice recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy","volume":"32","author":"Sharma","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2026092410311012600_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40262-021-01093-z","article-title":"Population pharmacokinetics of melphalan in a large cohort of autologous and allogeneic hematopoietic cell transplantation recipients: towards individualized dosing regimens","volume":"61","author":"Shah","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2026092410311012600_bib31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.19122","article-title":"Busulfan\u2013fludarabine- or treosulfan\u2013fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: a study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties","volume":"204","author":"Cseh","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"2026092410311012600_bib32","doi-asserted-by":"crossref","first-page":"702.e1","DOI":"10.1016\/j.jtct.2023.08.016","article-title":"Treosulfan-based conditioning regimen in pediatric hematopoietic stem cell transplantation: a retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)","volume":"29","author":"Gal\u00e1n","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2026092410311012600_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41409-023-02135-9","article-title":"Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial","volume":"59","author":"Sykora","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2026092410311012600_bib34","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41409-019-0550-0","article-title":"Haploidentical CD3 or \u03b1\/\u03b2 T-cell depleted HSCT in advanced stage sickle cell disease","volume":"54","author":"Foell","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2026092410311012600_bib35","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41409-025-02546-w","article-title":"\u03b1\u00df T-cell depleted haploidentical stem cell transplantation for pediatric and young adult patients with transfusion-dependent thalassemia","volume":"60","author":"Kleinschmidt","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2026092410311012600_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non-\u03b20\/\u03b20 genotype \u03b2-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"2026092410311012600_bib37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2026092410311012600_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/bmt.2008.133","article-title":"Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis","volume":"42","author":"Baker","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2026092410311012600_bib39","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/bloodadvances.2020001748","article-title":"Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis","volume":"4","author":"Felber","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2026092410311012600_bib40","doi-asserted-by":"crossref","first-page":"e27010","DOI":"10.1002\/pbc.27010","article-title":"Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning","volume":"65","author":"Shadur","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2026092410311012600_bib41","doi-asserted-by":"crossref","first-page":"e28523","DOI":"10.1002\/pbc.28523","article-title":"Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning","volume":"67","author":"Wustrau","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2026092410311012600_bib42","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.bbmt.2019.05.005","article-title":"Gonadal function after busulfan compared with treosulfan in children and adolescents undergoing allogeneic hematopoietic stem cell transplant","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2026092410311012600_bib43","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41409-020-0866-9","article-title":"Anti-M\u00fcllerian hormone and inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens","volume":"55","author":"Leiper","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2026092410311012600_bib44","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00277-021-04732-4","article-title":"Busulfan\u2013fludarabine- or treosulfan\u2013fludarabine-based myeloablative conditioning for children with thalassemia major","volume":"101","author":"L\u00fcftinger","year":"2022","journal-title":"Ann Hematol"},{"key":"2026092410311012600_bib45","doi-asserted-by":"crossref","first-page":"1653344","DOI":"10.3389\/fimmu.2025.1653344","article-title":"Next generation targeted non-genotoxic conditioning for hematopoietic stem cell and hematopoietic stem cell-based gene therapy","volume":"16","author":"Okalova","year":"2025","journal-title":"Front Immunol"},{"issue":"9","key":"2026092410311012600_bib46","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41591-025-03817-1","article-title":"Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial","volume":"31","author":"Agarwal","year":"2025","journal-title":"Nat Med"},{"issue":"22","key":"2026092410311012600_bib47","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood.2025031858","article-title":"Nonmyeloablative conditioning combined with anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS","volume":"147","author":"Muffly","year":"2026","journal-title":"Blood"},{"issue":"suppl 1","key":"2026092410311012600_bib48","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2024-200214","article-title":"Adding CD117 antibody to alemtuzumab, low dose total body irradiation (TBI), and sirolimus for matched related donor (MRD) hematopoietic cell transplant (HCT) in sickle cell disease (SCD): initial results","volume":"144","author":"Hsieh","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026092410311012600_bib49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2026092410311012600_bib50","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1038\/s41467-023-41153-5","article-title":"Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model","volume":"14","author":"Uchida","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"2026092410311012600_bib51","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.ymthe.2024.03.032","article-title":"Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant","volume":"32","author":"Yeung","year":"2024","journal-title":"Mol Ther"},{"issue":"7","key":"2026092410311012600_bib52","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/bloodadvances.2025018176","article-title":"Clonal dynamics, tolerance, and adverse events after CD45-ADC\u2013conditioned autologous HSPC transplantation in macaques","volume":"10","author":"Hayal","year":"2026","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026092410311012600_bib53","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2025-5871","article-title":"Refined design of a CD117 antibody-drug conjugate safely and effectively conditions non-human primates for autologous transplant-based gene therapy","volume":"146","author":"Gorfinkel","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026092410311012600_bib54","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2024-204403","article-title":"CD117 antibody conditioning and multiplex base editing enable rapid and robust fetal hemoglobin reactivation in a rhesus autologous transplantation model","volume":"144","author":"Demirci","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6118\/2587705\/blooda_adv-2026-019856-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6118\/2587705\/blooda_adv-2026-019856-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:31:39Z","timestamp":1790260299000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6118\/569589\/Alternative-conditioning-regimens-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":54,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019856","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,9]]}}}